Nicoletta Provinciali Marco Greppi Silvia Pesce Mariangela Rutigliani Irene Maria Briata Tania Buttiron Webber Marianna Fava Andrea DeCensi Emanuela Marcenaro
10.3389/fimmu.2022.1094017
Front Immunol
2022 Dec 19;13:1094017.
pd-1 pd-l1 avelumab immunotherapy ovarian cancer
CC BY
https://pubmed.ncbi.nlm.nih.gov/36601114/
Antineoplastic Agents / pharmacology Ovarian Neoplasms / drug therapy
Antineoplastic Agents / pharmacology Ovarian Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Antibodies, Monoclonal / therapeutic use Bevacizumab Female Humans Immunotherapy Antibodies, Monoclonal Antineoplastic Agents Bevacizumab
PMC9806340
36601114
Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
2022